Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel may discuss telavancin

Theravance (THRX) said FDA's Anti-Infective Drugs Advisory Committee may soon meet to review an NDA for telavancin to treat complicated

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE